Head-To-Head Review: ANI Pharmaceuticals (ANIP) versus The Competition

ANI Pharmaceuticals (NASDAQ:ANIP) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare ANI Pharmaceuticals to related businesses based on the strength of its valuation, analyst recommendations, earnings, risk, profitability, institutional ownership and dividends.

Volatility and Risk

ANI Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals’ rivals have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ANI Pharmaceuticals and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0	4	3	0	2.43
ANI Pharmaceuticals Competitors	7820	13783	25793	1036	2.41

ANI Pharmaceuticals currently has a consensus target price of $100.00, suggesting a potential upside of 40.73%. As a group, “Pharmaceuticals” companies have a potential upside of 24.75%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than its rivals.

Earnings and Valuation

This table compares ANI Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37 million	$78.34 million	14.16
ANI Pharmaceuticals Competitors	$3.54 billion	$3.17 billion	553.75

ANI Pharmaceuticals’ rivals have higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

76.0% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ANI Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.22%	28.34%	11.18%
ANI Pharmaceuticals Competitors	-2,393.19%	-220.45%	-16.12%

Summary

ANI Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.